AZTEC-CF

Details

Therapeutic approach
Anti-Infective
Trial status
Closed with results Participating Centres
Trials Tracker ID
TT001726
Last updated
24/02/2020

Full title

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Study details

This study aims to investigate whether it is safe and effective to use one inhaled antibiotic and one via a drip, instead of the current standard of practice of two antibiotics via a drip. Participants will receive the two different treatments the next two occasions they need to be admitted to Liverpool Heart & Chest Hospital with a chest infection. On one admission they will receive two IV antibiotics, on the other admission they will receive one IV antibiotic and inhaled aztreonam (known as Cayston®). The order they receive each treatment will be picked at random. Participants will have measurements taken including lung function tests, blood tests, CF quality of life questionnaires, and sputum samples will be sent to the University of Liverpool for advanced analysis of the effect each treatment has on bugs in the lung. It is hoped that this study may help provide more information toward a much needed expansion of therapeutic options available in CF.


Phase
Phase 4
Length of participation
2 exacerbations
Recruitment target
16
CF sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
CF sponsor type
Academic

Who can take part?

Age range
18 years and older
Including people

18 - 65 years old Pseudomonas aeruginosa in last 6 months
Pseudomonas aeruginosa in last 6 months
FEV1 25-75%

Excluding people

Already prescribed regular Cayston
Previous organ transplant
Documented allergy to beta-lactam antibiotics or IV Colistin

Get in touch

Your donation will make a difference:

Select amount
Select amount

CF centres running this trial

Closed

Liverpool Heart and Chest Hospital

NHS Trust
Liverpool Heart and Chest Hospital NHS Foundation Trust
Address
Thomas Drive
Liverpool
L14 3PE
Local site investigator
Freddy Frost